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PURPOSE: To evaluate the repair process in rats with experimentally induced arterial hypertension. This study aimed
to evaluate lesions in the ventricular myocardium and the repair process during experimental hypertension induced by
systemic blockage of nitric oxide using N-omega-nitro-L-arginine methyl ester hydrochloride (L-NAME). Nitric oxide is an
endothelial vasorelaxing factor and is necessary for the maintenance of normal arterial pressure, and L-NAME is an analog
and antagonist of L-arginine, the substrate of the nitric oxide synthase.
MATERIALS AND METHODS: We used 26 normotensive young male Wistar rats belonging to several litters. Animals
were treated with oral administration of L-NAME dissolved in water (75 mg/100 mL) for 43 days . Hearts were weighed and
processed by routine methods. Special stains utilized were Gomori’s trichrome (aniline blue), picrosirius red polarization to
identify fibrillar collagen, alcian blue technique (pH 0.5 and pH 2.5) to identify glycosaminoglycans, periodic acid-Schiff
technique (with and without amylases) to identify proteoglycans, and Weigert’s resorcinol fuchsin solution (with and
without oxone) to identify elastic fibers.
RESULTS: The results showed significant elevation of the arterial pressure (P <0.01) and significant increase of
cardiac weight (P <.0001) in the L-NAME (hypertensive) treated group, as compared to an untreated control group. The
histological analysis demonstrated wide infarcted myocardial areas in animals with nitric oxide blockade; several vascular
changes such as thickening of the muscular tunica with fibrosis; thickening in the wall of small arteries and arterioles; and
fibrinoid necrosis in the wall to nearly complete luminal obliteration. Reparative fibrosis involved mainly oxytalan elastic
and collagen fibers.
CONCLUSION: Oxytalan elastic and collagen fibers are of great importance for the postinfarct repair process occurring
during experimental nitric oxide inhibition.
KEYWORDS: Oxytalan elastic fibers. Collagen fibers. Nitric oxide. Arterial hypertension. Repair.
Hypertension is a common disorder in modern indus-
trial countries.1 In men, arterial hypertension is the most im-
portant risk factor in cardiovascular disease, affecting 11%
to 20% of the Brazilian population over 20 years of age. In
Brazil, cardiovascular diseases are the number-one cause of
mortality, representing about 30.8% of the total deaths.2
About 90% to 95% of arterial hypertension is idiopathic,
and the remaining 5% to 10% is largely secondary to renal
disease. About 5% of hypertensive patients experience sharp
blood pressure elevation, which if untreated, leads to death
in 1 or 2 years.3 Arterial hypertension is the most important
etiologic factor associated with the appearance of sympto-
matic heart failure, and left ventricular hypertrophy is the
major risk factor.4 Ventricular hypertrophy also occurs in as-
sociation with various forms of arrhythmia and is a risk fac-
tor in cardiac sudden death.5
Hypertension is a hemodynamic disorder characterized
by elevation of the arterial pressure, and increased vascular
resistance is its hemodynamic hallmark.6 Control of blood
pressure is complex; it is determined by the interaction of
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multiple genetic and environmental factors.3 Even if some
authors disagree,7 it is now well established that reduced ac-
tivity of nitric oxide synthase is, at least in some cases, a
pathogenic factor in development of hypertension.8-11
Nitric oxide (NO) is an endothelial vasorelaxing fac-
tor.12-17 N-omega-nitro-L-arginine-methyl ester (L-NAME) is
an analog and antagonist of L-arginine, the substrate of ni-
tric oxide synthase . Nitric oxide synthesis is necessary for
the maintenance of normal arterial pressure, and its block-
age causes arterial hypertension, significant experimental
cardiac hypertrophy, and lesions in the myocardium.18-27 The
extent of the direct influence of NO and the influence of
hypertension produced by NO blockage on hypertrophy
and on cardiac lesions is at present the subject of contro-
versy and is subject to study using the L-NAME model. Re-
duction of arterial hypertension in this model does not sig-
nificantly reduce cardiac hypertrophy or the lesions brought
about by an NO deficit, these morbid processes are prob-
able mainly related to the NO deficit, not the hyperten-
sion.25-26,28
The purpose of this work was to study lesions in ven-
tricular myocardium mainly concerning oxytalan elastic and
collagen fibers of rats at day 43 of arterial hypertension in-
duced by NO synthetase blockage (L-NAME model).
MATERIALS AND METHODS
Twenty-nine young normotensive adults Wistar rats from
several breeds with initial weights ranging from 179 to 279
grams were used. Arterial pressure was obtained on the 40th
day of the experiment using pletismography.20,27,29 To en-
sure that animals were normotensive, arterial pressure was
measured a day before the beginning of the experiment. Af-
ter arterial pressures and weights were measured, animals
were placed in plastic boxes with no more than 5 to 6 ani-
mals per box. The initial arterial pressure was not above
117 mm Hg in any animal (Table 1). Seventeen rats were
treated for 43 days with L-NAME (N-omega-nitro-L-ar-
ginine methyl ester hydrochloride, Sigma Chemical, St.
Louis) via oral administration at a concentration of 75 mg/
100 mL in drinking water (about 60 mg/kg of body
weight).20,27 Nine rats were used as an untreated control
group. Six hypertensive animals died during the experi-
ment, the majority at days 41 to 43.
At day 43 of the experiment, each animal was
anesthetized with ethyl ether, weighed, the thorax opened,
and cardiotomy performed. The hearts were weighed, fixed
in Bouin’s fixative for 48 hours, processed using routine
methods (embedded in Paraplast), and sliced into 6 or 7 mm
sections. Sections were stained with Gomori’s trichrome,
using aniline blue instead of fast green; picrosirius red, by
which fibrillar collagen (probable type I) takes on a red or
yellow color and reticular collagen (probable type III) takes
on a green color under polarized light; alcian blue tech-
nique at pH 0.5 to differentiate sulfated glycosamino-
glycans and at pH 2.5 to differentiate carboxylated and
phosphated glycosaminoglycans; periodic acid-Schiff tech-
nique with and without amylase to differentiate proteo-
glycans; and Weigert’s resorcinol fuchsin solution with and
without oxone. The periodic acid-Schiff technique with
amylase is important for differentiating proteoglycans be-
cause it removes glycogen from the tissue.30-31 The treat-
ment with Weigert’s resorcinol fuchsin solution using oxone
is important because the oxone produces oxidation, which
reveals the oxytalan fibers.
RESULTS
Our results demonstrate a sharp elevation of arterial pres-
sure in rats treated with L-NAME (hypertensives) compared
to the control group (Table 1). The mean tail-cuff pressure
in hypertensive rats before cardiotomy (at day 40) was 176
mm Hg (range, 160 to -198 mm Hg). The control group had
a mean value of 116 mm Hg before cardiomiotomy (range
100 to -123 mm Hg). Additionally, at day 40, there was a
significant difference in mean cardiac weight (P <.001) be-
tween control (0.86 g, standard error = 0.04) and treatment
(1.25 g, standard error = .005) groups. The ratio of cardiac
weight (mg):body weight (g) was significantly different be-
tween groups (P <.001), with values of 3.30 for the control
and 5.38 for the hypertensive group.
Figures 1 to 3 show examples of the histological results
of the control and hypertensive groups. The histological
analysis revealed that intense reactive and reparative fibro-
sis occurred in all layers of myocardium (subepicardial,
subendocardial, and inner myocardium) in left and right
ventricles of treated animals. The right ventricles were more
affected. These results suggested that wide infarcted areas
Table 1 - Tail-cuff arterial pressure measured during the experiments (mean / standard error).
Control (mm Hg) L-NAME (mm Hg)
Initial arterial pressure. 116.87 / 0.84 (n = 9) 115.65 / 0.82 (n = 17)
Arterial pressure at day 40. 110.11 / 2.15 (n = 9) 175.64 / 3.19 (n = 11)
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had developed in the myocardium. We also documented
several vascular changes, such as thickening of the muscu-
lar tunica with fibrosis replacing part of the cells, narrow-
ing of the lumina, and perivascular fibrosis sometimes show-
ing dense collagen fibers. We observed systematically a
marked thickening in the wall of small arteries and arterioles
of the hypertense animals and fibrinoid necrosis in the wall
to nearly complete luminal obliteration (Figures 1 and 2).
In the fibrotic areas, we found the fibrillar collagen (prob-
able type I) occupying a great proportion of total collagen.
Occurrence of fibrillar collagen in reticular disposition
(probable type III) was less significant. In spite of the in-
tense fibrosis found in the hypertensive animals, the ratio
of fibrillar to reticular collagens in these fibrotic areas was
similar to that of the myocardial interstitium of the control
group (Figure 2). Weigert’s staining for elastic fibers was
Figure 1 - Panoramic view of heart sections showing hypertrophy and fibrotic scars (dark areas) in the hypertensive hearts (a) compared with
control hearts (b) stained with picro-sirius red; (c) myocardium of a control animal showing fibrillar collagen (in yellow, orange, or red)
corresponding to a high proportion of collagen, with a small amount of reticular collagen (in green) (magnification 100X) (picro-sirius red
polarization).
(c)(b)(a)
Figure 2 - (a) inflammatory infiltrate areas highly suggestive of a myocardial infarct in the subendocardial region of a hypertensive heart
(magnification 100X); (b) postinfarct fibrotic areas in the right ventricular myocardium of a hypertensive animal, stained with picrosirius red
using polarized light to show fibrillar collagen (in yellow, orange, or red) occupying a great proportion of collagen fibers (magnification 200X);
(c) postinfarct fibrotic areas in the myocardium of a hypertensive animal, showing fibrillar collagen (in yellow, orange, or red) corresponding
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highly positive in the majority of the fibrotic areas, but in
perivascular fibrotic areas reactivity was nil for all elastic
fibers (Figure 3). Weigert’s staining with oxone was more
intense than that without oxone. Alterations in the concen-
tration of the sulfated glycosaminoglycans or carboxylated
or phosphated glycosaminoglycans in the myocardial mass
using the alcian blue technique could not be assessed be-
cause there was no reaction.
We did not find fibrotic areas in the myocardium in the
control animals. These animals had vessels with character-
istic normal appearance.
DISCUSSION
Nitric oxide (NO) is involved in several important sig-
nal processes in cardiovascular, nervous, and immunologic
systems and also functions as a modulator of extracellular
matrix components.15,32-37 Nitric Oxide is produced by car-
diac myocytes38 and also acts in the myocardium as a re-
laxing factor.22 Under physiological conditions, NO plays
an important role in regulation of tissue perfusion and myo-
cardial blood flow.39 The interruption of NO synthesis by
L-NAME causes systemic arterial hypertension and signifi-
cant cardiac hypertrophy and lesions (reactive and repara-
tive fibrosis) in the myocardium.20,21,25-28 This experimental
arterial hypertension can be reversed using captopril,
losartan, hydralazine, and enalapril.4,20,23,25,28 The adminis-
tration of L-arginine (the NO synthase substrate) in rodents
treated with L-NAME reverses this experimental arterial
hypertension;19 in some cases of human hypertension, the
administration of L-arginine reverses the hypertensive dis-
ease.9,11
Fibrosis occurs in the myocardium during myocardial
hypertrophy due to arterial hypertension. Fibrosis may oc-
cur between the cardiac myocytes (reactive or interstitial
fibrosis) or secondary to myocyte necrosis (reparative or
parenchymal fibrosis, or, scarring). After about 4 weeks of
renovascular hypertension, reactive fibrosis occurs, and at
12 weeks, reparative fibrosis appears predominantly in
endomyocardium of rats. In diastolic dysfunction (because
of a pathological increase of myocardial stiffness), its ma-
jor determinant is the tissue component with highest ten-
sile strength, which is the collagen matrix of the myocar-
dium. Type I collagen, which is predominant in the
myocardium¯in rats and monkeys about 70% and 82%, re-
spectively, followed by type III at about 20% and 11%¯has
great tensile strength, and its concentration determines the
stiffness of myocardial tissue. Thus, the origin of heart fail-
ure in arterial hypertension with diastolic dysfunction of
the left ventricle appears to be rooted in the structural
remodeling of the myocardium, particularly in the devel-
opment of myocardial fibrosis.4 As the infarcted area heals,
the late and persistent arrhythmogenic potential that
emerges is not primarily dependent on the effects of
ischemia on cellular electrophysiology but rather on the al-
teration of the tissue structure stability originating in the
postinfarct reparative fibrosis.40
The ideal repair mechanism is not found in adult tis-
sue, but rather in embryonic tissue. Because of its relative
easy and ideal healing ¯ rapid, efficient, and perfect with-
out leaving a scar ¯ embryonic tissue is studied as a favorite
paradigm of efficient tissue repair. Identifying how embry-
onic tissue heals will lead to new therapeutic strategies for
improving adult wound healing.41
Ribeiro et al.,20 observed that rats treated with L-NAME
presented a progressive significant increase of the tail-cuff
arterial pressure (168 mm Hg at day 30). They also observed
systematically a marked thickening in the wall of small ar-
teries and arterioles. They found fibrinoid necrosis in the
wall of the renal arterioles and nearly complete luminal ob-
Figure 3 - (a) Myocardium with intense reaction by oxytalan fibers
(dark dots) of the elastic system in reparative fibrotic areas (Weigert’s
resorcinol-fuchsin method using an oxone reaction; magnification
100X); (b) perivascular fibrosis characteristic of the hypertensive cardiac
processes using the L-NAME model. Note the degeneration of the
inner elastic lamina and lack of reaction for oxytalan fibers of the
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literation in 27% of the cases. Fibrinoid necrosis, which may
result in small infarct areas, is the primary histopathologi-
cal indication of malignant arterial hypertension.42
In infarcted areas after experimental coronary occlusion
in rabbits, there was a 10-fold increase in the inducible form
nitric oxide synthase activity.43
In the present work with the L-NAME rat model, we con-
firm previously reported data regarding a sharp and signifi-
cant increase of the arterial pressure. We found both reac-
tive and reparative fibrosis (including perivascular fibro-
sis). We also verified several vascular changes, such as thick-
ening of the muscular tunica with fibrosis replacing part of
the cells, narrowing of the lumina, and perivascular fibro-
sis, sometimes with dense collagen fibers. Weigert’s stain-
ing both with and without oxone oxidation was highly posi-
tive in the majority of the fibrotic areas. Nevertheless, in
perivascular fibrotic areas, the reactivity for Weigert’s fibers
was low and concerning oxytalan fibers was nil, probably
involved with a lack of major stiffness of the vessels.
The oxone reaction has a high reactivity for oxytalan
fibers. Weigert’s resorcinol fuchsin method using oxone
oxidation is used to identify oxytalan fibers, staining them
violet. The Weigert’s resorcinol fuchsin method without
oxone oxidation is used to identify the other fibers of the
elastic system.44-45 The occurrence of oxytalan fibers serves
to explain at least in part the stiffness of the tissue during
diastolic function, because oxytalan fibers are less disten-
sible than the other fibers of the elastic system.46
We systematically observed a marked thickening in the
wall of small arteries and arterioles of the L-NAME treated
hypertense animals and fibrinoid necrosis in the wall nearly
to complete luminal obliteration. We also suggest that myo-
cardial lesions occurred by vasoconstriction (mainly of
arterioles) and by the hypertrophic condition of myocytes
leading to local hypoperfusion and ischemia as well as pos-
sibly by a degenerative processes of segments of the vas-
cular bed in affected regions because of the obstructions.
Concerning myocardial lesions that occur because of va-
soconstriction, it is well known that in some cases, infarc-
tion occurs after vascular spasm.3 Reactive fibrosis (perivas-
cular and perimyocyte) possibly occurs by simple interrup-
tion of NO production that would induce collagen prolif-
eration.34-35, 38
In this work, we identified in the heart of hypertensive
animals intense perivascular fibrosis and scarring of the vas-
cular wall in the affected vascular bed. In the development
of cardiac hypertrophy (along the cardiac interstitial
remodeling) an abnormal accumulation of fibrillar collagen
with thickening of adventitia in the intramyocardial coro-
naries also occurs.47 The analysis of Fischer et al.,1 follow-
ing the inducement of arterial hypertension using stenosis
of the left renal artery, an interstitial and perivascular focal
fibrosis in the heart of hypertensive animals was found. In
our material, reparative fibrosis was predominant, and we
found a discreet cellular inflammatory infiltration in the le-
sions. This occurred because we studied animals at day 43
of administration of L-NAME, and therefore old reparative
areas were present. Lukic et al.,48 studying diabetes mellitus
in a mouse model, found mild inflammatory infiltration,
mainly concerning some cellular types and indicated that
NO played an important role in these processes. Consider-
ing all factors implicit in the origin of hypertensive dis-
ease in men, at least in some cases, the reduction of NO
levels is significantly involved.11,49-51 Our present results are
also similar to the abnormalities and lesions occurring, at
least in some cases, in hypertension, cardiomyopathies, and
in arteriosclerosis.
In the present work, we found cardiac hypertrophy at
day 40 by comparing the mean of cardiac weight of the
control group with cardiac weight of the hypertensive
group. There was a significant difference in the cardiac
weight (mg)/ body weight (g) ratio, with values of 3.30 for
the control group and 5.38 for the hypertensive group. Hy-
pertension is the most important etiologic factor associated
with the appearance of symptomatic heart failure, and left
ventricular hypertrophy is the major risk factor.4 Hyper-
trophic heart growth is in most cases considered to be in-
duced by hemodynamic overload. However, the degree of
hypertrophy is variable and is poorly correlated with the
degree of arterial pressure, and is usually concentric. In
some patients, the heart may double its weight; however,
in others with the same arterial overload pressure - even af-
ter several years - the heart may undergo only a slight
hypertrophy.42 The hypertrophic process that occurs in the
L-NAME model is in some cases poorly correlated with the
arterial pressure level27,49-54; however, when hypertrophy oc-
curs, it is generally concentric.49 The diastolic dysfunction
of the heart usually decreases when hypertrophy is reverted
by administration of angiotensin-converting-enzyme inhibi-
tors or calcium-channel antagonists.55 Some authors propose
that this occurs not only because of the reduction of hyper-
trophy, but also because of the ability of antihypertensives
to reduce the collagen concentration.47 The use of hydrala-
zine or alpha-methyldopa to stimulate the reduction of
hypertrophy has been hypothesized to increase fibrotic tis-
sue.55 Our studies with hydralazine did not confirm this
data.50 Some drugs, such as the angiotensin receptor antago-
nist, losartan;20 the calcium channel blocker, verapamil;21
the vasodilator with some mecanism mainly as a calcium
channel blocker, hydralazine25; and the angiotensin-con-
verting-enzyme inhibitors, captopril,23 enalapril,28 and
trandolapril,21 revert increased arterial pressure induced by
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L-NAME. In our laboratory we have used hydralazine
(Sigma Chemical, St. Louis) at a concentration of 120 mg/
L25 as well as the commercial preparation (tablet, Ciba-
Geigy) at a concentration of 36 mg/L and 120 mg/L. The
dose of 120 mg/L reverted arterial pressure and postponed
the abnormalities that occur during systemic nitric oxide
blockage by L-NAME.50 During renovascular hypertension,
pretreatment using captopril has been suggested to prevent
hypertension, fibrosis, and hypertrophy of the left ventri-
cle.4 An important question is whether the regression of
myocardial hypertrophy is linked to the reduction of car-
diovascular risk induced by hypertrophy.55 Nevertheless, the
cardiovascular risk may also increase in some cases, for in-
stance, when the hypertrophy is produced by a myocardial
infarct.6 Vasodilators and diuretics reduce arterial pressure,
however, they are not believed to reduce the cardiac weight
significantly. It also has been proposed that regression of
hypertrophy is only reached when sympathetic activity is
reduced, because the sympathetic system is one of the cru-
cial factors for the development of the hypertrophy.55
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RESUMO
XAVIER-VIDAL R Fibras elásticas oxitalânicas e fibras
colágenas durante o processo de reparo na inibição ex-
perimental do óxido nítrico. CLINICS 60(2):85-93,
2005.
OBJETIVO: Avaliar o processo de reparo em ratos sub-
metidos à hipertensão arterial experimental. Avaliamos le-
sões miocárdicas ventriculares e processos de reparo durante
a hipertensão arterial experimental induzida pelo bloqueio
da síntese do óxido nítrico (ON) utilizando o Hidrocloreto
de L-NAME. ON é um fator de relaxamento endotelial e é
necessário para a manutenção da pressão arterial normal.
L-NAME é um analogo e antagonista da L-Arginine que é
o substrato da enzima óxido nítrico sintase.
MATERIAL E MÉTODOS: Utilizamos 26 ratos Wistar
normotensos jovens oriundos de diversas ninhadas. Os ani-
mais foram submetidos ao L-NAME (Hidrocloreto de Nw-
nitro-L-arginina metil ester) por administração via oral em
água durante 43 dias (concentração: 75 mg / 100 ml). Os
corações foram pesados e processados por métodos de roti-
na. Colorações Especiais utilizadas foram Tricrômico de
Gomori (azul de anilina), Picro-Sirious Red sob luz polari-
zada para identificar as fibras colágenas, Técnica do Alcian
Blue (pH 0,5 e pH 2,5) para identificar as glicosamino-
glicanas, Técnica do Ácido Periódico Schiff (com e sem
amilase) para identificar as proteoglicanas e Resorcina
Fucsina de Weigert’s (com e sem oxona) para identificar as
fibras elásticas.
RESULTADOS: Os resultados demonstram elevação
significativa da pressão arterial (p<0,01) e significativo au-
mento do peso cardíaco (p<0,001) no grupo tratado com
L-NAME (hipertenso), comparado com um grupo de con-
troles não tratados. As análises histológicas demonstraram
nos animais submetidos ao bloqueio da síntese do óxido
nítrico amplas áreas de infarto no miocárdio, várias anor-
malidades vasculares como espessamento da túnica mus-
cular com fibrose, espessamento da parede de pequenas ar-
térias e arteríolas e, ainda, necrose fibrinóide levando à
completa obliteração luminal. A fibrose reparativa teve prin-
cipal presença de fibras elásticas oxitalânicas e fibras
colágenas.
CONCLUSÃO: As fibras elásticas oxitalânicas e fibras
colágenas são de grande importância para o processo de re-
paro pós-infarto que ocorre na inibição experimental do
óxido nítrico.
UNITERMOS: Fíbras Elásticas Oxitalânicas. Fibras
Colágenas. Óxido Nítrico. Hipertensão Arterial. Reparo.
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